@article{52014e5d73f047ed889c0306512d2fc7,
title = "Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes: Diabetes, Obesity and Metabolism",
abstract = "Residual inflammatory risk (RIR) is defined as persistent circulating levels of high sensitivity C-reactive protein (hs-CRP) >2 mg/L despite an optimal (",
keywords = "body mass index, cardiovascular diseases, c-reactive protein, diabetes complications, ischaemic heart disease, LDL-cholesterol, obesity, residual inflammatory risk, type 2 diabetes, waist-hip ratio, C reactive protein, cholesterol, glinide derivative, glucose, hydroxymethylglutaryl coenzyme A reductase inhibitor, insulin, low density lipoprotein cholesterol, metformin, oral antidiabetic agent, sulfonylurea derivative, triacylglycerol, unclassified drug, aged, Article, body mass, cardiovascular disease, cholesterol blood level, cohort analysis, controlled study, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, drug use, female, glycemic control, high risk patient, human, inflammation, insulin resistance, kidney failure, major clinical study, male, non insulin dependent diabetes mellitus, obesity, peripheral vascular disease, prevalence, protein blood level, residual inflammatory risk, retrospective study, triacylglycerol blood level, waist hip ratio",
author = "F. Prattichizzo and A. Giuliani and J. Sabbatinelli and G. Matacchione and D. Ramini and A.R. Bonfigli and M.R. Rippo and {de Candia}, P. and A.D. Procopio and F. Olivieri and A. Ceriello",
note = "Cited By :9 Export Date: 5 March 2021 CODEN: DOMEF Correspondence Address: Prattichizzo, F.; IRCCS MultiMedicaItaly; email: francesco.prattichizzo@multimedica.it Chemicals/CAS: C reactive protein, 9007-41-4; cholesterol, 57-88-5; glucose, 50-99-7, 84778-64-3; insulin, 9004-10-8; metformin, 1115-70-4, 657-24-9 References: Ridker, P.M., Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin (2016) Eur Heart J., 37 (22), pp. 1720-1722; Ridker, P.M., How common is residual inflammatory risk? (2017) Circ Res., 120 (4), pp. 617-619; Aday, A.W., Ridker, P.M., Antiinflammatory therapy in clinical care: the CANTOS trial and beyond (2018) Front Cardiovasc Med., 5, p. 62; Ridker, P.M., Everett, B.M., Thuren, T., Antiinflammatory therapy with Canakinumab for atherosclerotic disease (2017) N Engl J Med., 377 (12), pp. 1119-1131; Ridker, P.M., MacFadyen, J.G., Everett, B.M., Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial (2018) Lancet., 391 (10118), pp. 319-328; Lu, Y., Zhou, S., Dreyer, R.P., Spatz, E.S., Sex differences in inflammatory markers and health status among young adults with acute myocardial infarction: results from the VIRGO (variation in recovery: role of gender on outcomes of young acute myocardial infarction patients) study (2017) Circ Cardiovasc Qual Outcomes., 10 (2); Hwang, Y.C., Morrow, D.A., Cannon, C.P., High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (examination of cardiovascular outcomes with Alogliptin versus standard of care) trial (2018) Diabetes Obes Metab., 20 (3), pp. 654-659; Kamari, Y., Bitzur, R., Cohen, H., Shaish, A., Harats, D., Should all diabetic patients be treated with a statin? (2009) Diabetes Care., 32, pp. S378-S383; Testa, R., Olivieri, F., Sirolla, C., Leukocyte telomere length is associated with complications of type 2 diabetes mellitus (2011) Diabet Med., 28 (11), pp. 1388-1394; Classification and diagnosis of diabetes: standards of medical care in diabetes—2020 (2020) Diabetes Care., 43, pp. S14-S31; Prattichizzo, F., Giuliani, A., Mens{\`a}, E., Pleiotropic effects of metformin: shaping the microbiome to manage type 2 diabetes and postpone ageing (2018) Ageing Res Rev., 48, pp. 87-98; Kalkman, D.N., Aquino, M., Claessen, B.E., Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions (2018) Eur Heart J., 39 (46), pp. 4101-4108; Kahn, S.E., Zinman, B., Haffner, S.M., Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes (2006) Diabetes., 55 (8), pp. 2357-2364; Sinha, S.K., Nicholas, S.B., Sung, J.H., Hs-CRP is associated with incident diabetic nephropathy: findings from the Jackson heart study (2019) Diabetes Care., 42 (11), pp. 2083-2089; Prattichizzo, F., La Sala, L., Ryd{\'e}n, L., Glucose- lowering therapies in patients with type 2 diabetes and cardiovascular diseases (2019) Eur J Prev Cardiol, 26, pp. 73-80; Prattichizzo, F., De Nigris, V., Micheloni, S., La Sala, L., Ceriello, A., Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? (2018) Diabetes Obes Metab., 20 (11), pp. 2515-2522; Blaum, C., Brunner, F.J., Kr{\"o}ger, F., Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: implications for an anti-inflammatory treatment target population (2019) Eur J Prev Cardiol., 10. , [Epub ahead of print]; Gaede, P., Lund-Andersen, H., Parving, H.H., Pedersen, O., Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) N Engl J Med., 358 (6), pp. 580-591",
year = "2020",
doi = "10.1111/dom.14081",
language = "English",
volume = "22",
pages = "1696--1700",
journal = "Diabetes Obes. Metab.",
issn = "1462-8902",
publisher = "Blackwell Publishing Ltd",
number = "9",
}